Moorman A V, Hagemeijer A, Charrin C, Rieder H, Secker-Walker L M
Department of Haematology, Royal Free Hospital School of Medicine, London, UK.
Leukemia. 1998 May;12(5):805-10. doi: 10.1038/sj.leu.2401016.
The EU Concerted Action Workshop on 11q23 Abnormalities in Hematological Malignancies collected 550 patients with abnormalities involving 11q23. Of these, 53 patients had a translocation involving chromosome 11, breakpoint q23, and chromosome 19, breakpoint p13. Karyogram review enabled each patient to be further defined as t(11;19)(q23;p13.1) (21 patients) or t(11;19)(q23;p13.3) (32 patients). There was a marked difference between the type of banding and the translocation identified: t(11;19)(q23;p13.1) was detected predominantly by R-banding, whereas t(11;19)(q23;p13.3) was detected almost solely by G-banding. Additional change was extremely rare in patients with t(11;19)(q23;p13.1) but occurred in nearly half of the patients with t(11;19)(q23;p13.3). Patients with t(11;19)(q23;p13.1) all had leukemia of a myeloid lineage, mostly acute myeloid leukemia (AML), and were predominantly adult. In contrast patients with t(11;19)(q23;p13.3) had malignancies of both myeloid and lymphoid lineage and were mainly infants less than 1 year old. The survival of both groups of patients was generally poor, over 50% of t(11;19)(q23;p13.1) patients died within 2 years of diagnosis and the median survival of acute lymphoblastic leukemia (ALL) patients with t(11;19)(q23;p13.3) was 17.6 months.
欧盟血液系统恶性肿瘤11q23异常协同行动研讨会收集了550例涉及11q23异常的患者。其中，53例患者存在涉及11号染色体q23断点和19号染色体p13断点的易位。核型分析使每位患者能够进一步被定义为t(11;19)(q23;p13.1)（21例患者）或t(11;19)(q23;p13.3)（32例患者）。所识别的条带类型与易位之间存在显著差异：t(11;19)(q23;p13.1)主要通过R显带检测到，而t(11;19)(q23;p13.3)几乎仅通过G显带检测到。在t(11;19)(q23;p13.1)患者中，额外的改变极为罕见，但在近一半的t(11;19)(q23;p13.3)患者中出现。t(11;19)(q23;p13.1)患者均患有髓系白血病，大多为急性髓系白血病（AML），且以成年人为主。相比之下，t(11;19)(q23;p13.3)患者患有髓系和淋巴系恶性肿瘤，主要是年龄小于1岁的婴儿。两组患者的生存率总体都很差，超过50%的t(11;19)(q23;p13.1)患者在诊断后2年内死亡，t(11;19)(q23;p13.3)的急性淋巴细胞白血病（ALL）患者的中位生存期为17.6个月。
